D.E. Shaw & Co’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-46,619
| Closed | -$2.41M | – | 5554 |
|
|
2022
Q3 | $2.41M | Buy |
46,619
+37,711
| +423% | +$1.56M | ﹤0.01% | 2834 |
|
|
2022
Q2 | $221K | Buy |
+8,908
| New | +$196K | ﹤0.01% | 4507 |
|
|
2021
Q4 | – | Sell |
-45,826
| Closed | -$1.61M | – | 5853 |
|
|
2021
Q3 | $784K | Sell |
45,826
-335,085
| -88% | -$5.22M | ﹤0.01% | 3785 |
|
|
2021
Q2 | $5.1M | Buy |
380,911
+153,638
| +68% | +$3.78M | ﹤0.01% | 2022 |
|
|
2021
Q1 | $11.6M | Sell |
227,273
-469,821
| -67% | -$28.3M | 0.01% | 1256 |
|
|
2020
Q4 | $43.2M | Sell |
697,094
-76,376
| -10% | -$4.37M | 0.04% | 565 |
|
|
2020
Q3 | $42.4M | Buy |
773,470
+650,920
| +531% | +$35M | 0.04% | 485 |
|
|
2020
Q2 | $7.05M | Buy |
122,550
+100,482
| +455% | +$5.47M | 0.01% | 1408 |
|
|
2020
Q1 | $887K | Sell |
22,068
-11,903
| -35% | -$505K | ﹤0.01% | 2825 |
|
|
2019
Q4 | $1.34M | Sell |
33,971
-19,446
| -36% | -$341K | ﹤0.01% | 2775 |
|
|
2019
Q3 | $363K | Sell |
53,417
-39,793
| -43% | -$299K | ﹤0.01% | 3357 |
|
|
2019
Q2 | $867K | Sell |
93,210
-33,149
| -26% | -$384K | ﹤0.01% | 2761 |
|
|
2019
Q1 | $1.76M | Sell |
126,359
-88,540
| -41% | -$1.01M | ﹤0.01% | 2237 |
|
|
2018
Q4 | $2.34M | Sell |
214,899
-44,938
| -17% | -$474K | ﹤0.01% | 2027 |
|
|
2018
Q3 | $3.29M | Sell |
259,837
-16,617
| -6% | -$200K | ﹤0.01% | 1851 |
|
|
2018
Q2 | $3.64M | Sell |
276,454
-76,413
| -22% | -$914K | ﹤0.01% | 1760 |
|
|
2018
Q1 | $4.8M | Buy |
352,867
+94,889
| +37% | +$979K | 0.01% | 1431 |
|
|
2017
Q4 | $1.53M | Buy |
257,978
+12,343
| +5% | +$84.7K | ﹤0.01% | 2324 |
|
|
2017
Q3 | $1.82M | Buy |
245,635
+4,071
| +2% | +$33.8K | ﹤0.01% | 2104 |
|
|
2017
Q2 | $2.26M | Sell |
241,564
-22,257
| -8% | -$163K | ﹤0.01% | 1899 |
|
|
2017
Q1 | $1.92M | Sell |
263,821
-79,604
| -23% | -$573K | ﹤0.01% | 1869 |
|
|
2016
Q4 | $2.54M | Buy |
343,425
+161,138
| +88% | +$1.16M | ﹤0.01% | 1816 |
|
|
2016
Q3 | $1.1M | Sell |
182,287
-11,702
| -6% | -$55.3K | ﹤0.01% | 2331 |
|
|
2016
Q2 | $871K | Sell |
193,989
-43,790
| -18% | -$164K | ﹤0.01% | 2496 |
|
|
2016
Q1 | $592K | Buy |
237,779
+50,893
| +27% | +$185K | ﹤0.01% | 2689 |
|
|
2015
Q4 | $1.51M | Buy |
186,886
+45,597
| +32% | +$323K | ﹤0.01% | 2346 |
|
|
2015
Q3 | $855K | Sell |
141,289
-27,906
| -16% | -$202K | ﹤0.01% | 2707 |
|
|
2015
Q2 | $1.39M | Buy |
169,195
+57,425
| +51% | +$456K | ﹤0.01% | 2459 |
|
|
2015
Q1 | $844K | Buy |
111,770
+10,612
| +10% | +$82.9K | ﹤0.01% | 2693 |
|
|
2014
Q4 | $691K | Buy |
101,158
+74,359
| +277% | +$393K | ﹤0.01% | 3101 |
|
|
2014
Q3 | $121K | Buy |
26,799
+12,298
| +85% | +$65K | ﹤0.01% | 3965 |
|
|
2014
Q2 | $85K | Buy |
+14,501
| New | +$81.4K | ﹤0.01% | 4092 |
|
|
2013
Q4 | – | Sell |
-63,702
| Closed | -$354K | – | 4764 |
|
|
2013
Q3 | $354K | Sell |
63,702
-22,459
| -26% | -$243K | ﹤0.01% | 3805 |
|
|
2013
Q2 | $1.22M | Buy |
+86,161
| New | +$1.12M | ﹤0.01% | 2550 |
|
Other funds holding CCXI
D.E. Shaw & Co's CCXI Position: Q4 2022 in Review
D.E. Shaw & Co sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 46,619 shares — an estimated $2.41M sold.
D.E. Shaw & Co first reported a position in CCXI in Q2 2013 and held it in 34 quarters. The position peaked at $43.2M in Q4 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- D.E. Shaw & Co reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- D.E. Shaw & Co sold 46,619 ChemoCentryx, Inc. shares in Q4 2022, an estimated $2.41M.
- D.E. Shaw & Co first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 34 quarters.
- D.E. Shaw & Co's ChemoCentryx, Inc. position peaked at $43.2M in Q4 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.